Neoadjuvant Apalutamide for Potency Preservation in High-Risk Prostate Cancer: A Randomized Trial - Isaac Kim
Isaac Kim
Isaac Kim presents a randomized three-arm trial of neoadjuvant apalutamide to Neeraj Agarwal, enrolling 74 to 76 high-risk prostate cancer patients andomized to apalutamide alone, apalutamide plus abiraterone plus ADT, or immediate surgery.
Radiographic Progression-Free Survival and Overall Survival Correlation in TALAPRO-2 - Neeraj Agarwal
Neeraj Agarwal
Neeraj Agarwal presents a correlation analysis from TALAPRO-2 examining whether radiographic progression-free survival predicts overall survival in the phase 3 trial of enzalutamide plus talazoparib in first-line mCRPC.
